← ANALYST RATINGS · TIPRANKS
NovaBridge Biosciences (NBP): analyst forecast and price target
Analyst consensus
Moderate Buy1 Buy0 Hold0 Sell
Ratings of 1 analysts in the last 3 months12-month forecast
Based on 1 price targets given in the last 3 months, the average target is $9.00, the highest $9.00, the lowest $9.00. The average is +614.3% from the last price of $1.26.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Andres Y. Maldonado★★★★★★★★★★#149 · hits 58% · avg +42.1% | H.C. Wainwright | $9.00 | Buy | +614.3% | Reiterated | 13.10.26on TipRanks 12:25 | −2.3%next day +0.3% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $1.50 | Hold | +19.0% | Reiterated | 13.10.26on TipRanks 05:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $1.50 | Hold | +19.0% | Reiterated | 13.10.26on TipRanks 05:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $1.50 | Hold | +19.0% | Reiterated | 13.10.26on TipRanks 05:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $1.50 → $1.00−33.3% | Sell | −20.6% | Downgrade | 13.10.26on TipRanks 05:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $1.50 | Hold | +19.0% | Reiterated | 13.10.26on TipRanks 05:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $1.50 | Hold | +19.0% | Reiterated | 13.10.26on TipRanks 05:05 | — | |
| Justin Zelin★★★★★★★★★★#4442 · hits 36% · avg +3.1% | BTIG | $9.00 | Buy | +614.3% | Reiterated | 06.01.26on TipRanks Jan 7 06:15 | −11.8%next day +3.4% · 5 days −6.2% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering NovaBridge Biosciences
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 13.10.26: target $9.00 at a price of $1.32 (+581.8%); now: $9.00 at $1.26 (+614.3%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 2 | 1 | 1 | 2 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Best top-analyst consensus in the sector · Healthcare
About NovaBridge Biosciences
- CEO: Srishti Gupta
- Employees: 30
- 2440 Research Boulevard, Rockville, MD, 20850, US
- www.novabridge.com
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor. Additionally, NovaBridge Biosciences has established collaborations with Bristol Myers Squibb for givastomig's advancement, ABL Bio, Inc. for both givastomig and ragistomig, and TJ Bio for uliledlimab. Founded in 2014 and headquartered in Rockville, Maryland, the entity was formerly named I-Mab, with its transition to NovaBridge Biosciences slated for October 2025.
Data from the stock’s TipRanks forecast page, read 422 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗